Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Immuneering (IMRX) will participate in the 23rd Annual Needham Virtual Healthcare Conference to discuss its pipeline, platform, and business strategy. The event will feature the CEO and CSO in Fireside Chat and Investor Meetings on April 11, 2024. Investors can watch the webcast on the company's website.

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer and Brett Hall, Chief Scientific Officer.

Format:	Fireside Chat and 1x1 Investor Meetings
Date/Time:	April 11 from 3-3:40 PM ET

The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.

Media Contact:
Gina Nugent 
Nugent Communications 
gina@nugentcommunications.com 

Investor Contact: 
Laurence Watts 
619-916-7620
laurence@newstreetir.com

FAQ

When will Immuneering participate in the 23rd Annual Needham Virtual Healthcare Conference?

Immuneering will participate in the 23rd Annual Needham Virtual Healthcare Conference from April 8-11, 2024.

Who will be participating from Immuneering in the conference?

Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer, will participate from Immuneering in the conference.

What is the format of Immuneering 's participation in the conference?

The format includes Fireside Chat and 1x1 Investor Meetings.

Where can investors watch the webcast of Immuneering 's presentation?

Investors can watch the webcast live and archived on the Investor Relations section of Immuneering's website.